


## To Whom It May Concern

Bioabsorbable polylactic/glycolic (PLGA) implants have been in clinical use in Europe and in USA more than 15 years. They have been applied also successfully in pediatric surgery, in fixation of bone fractures in children, as enclosed references show. As far as we know, there is no evidence in the scientific literature, which should show that PLGA implants are oncogenic. Bioretec's Activa PLGA implants have not been studied specifically in the fixation of growth plate fractures in children. Earlier we were involved in the development of PLGA implants indicated especially for the fixation of bone fractures in children, which were in the market for more than 15 years.



**Pertti Törmälä**

Ph.D., M.D. Sci.h.c., B.M.S., Professor  
CSO

Bioretec Ltd.  
Saarenkärjenkuja 5 As. 2 (home office)  
FI-33300 Tampere, Finland  
Mobile +358 40 514 6944  
Fax +358 3 343 4820  
[Pertti.Tormala@bioretec.com](mailto:Pertti.Tormala@bioretec.com)  
[www.bioretec.com](http://www.bioretec.com)



**Pertti Viitanen**

Managing Director, CEO

Bioretec Ltd.  
Hermiankatu 22, Modulight building  
P.O.Box 135  
FI-33720 Tampere, Finland  
Mobile + 358 400 634 580  
[Pertti.Viitanen@bioretec.com](mailto:Pertti.Viitanen@bioretec.com)

## Appendix:

080515 Biocompatibility evaluation for ActivaPin Product Group

100707 Physeal fractures\_Literature notes

111125 Status of clinical investigation Antebrachium diaphysis A228\_CIP\_1